Physician profile
Sanjeev Gopal
NPI 1003821430
$6,995.03
in general payments reported to CMS, 2019-2025
62 companies · $1,787 in 2025
The $1,787 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,979 · 2020: $27.04 · 2021: $11.92 · 2022: $834 · 2023: $1,103 · 2024: $1,254 · 2025: $1,787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,631 · Education: $512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,631.21 |
| Education | $511.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $479.64 | 2019-2024 | Padcev |
| Astrazeneca Pharmaceuticals Lp | $451.01 | 2019-2025 | Lynparza, Imfinzi, Enhertu |
| Janssen Biotech, INC. | $410.71 | 2019-2025 | Carvykti, Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $375.52 | 2019-2025 | Opdivo, Opdualag |
| Pfizer INC. | $323.81 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $303.81 | 2019-2025 | Keytruda, Lynparza |
| Abbvie INC. | $293.84 | 2023-2025 | |
| Celgene Corporation | $292.49 | 2019-2025 | Reblozyl, Opdivo, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $283.72 | 2019-2023 | |
| Incyte Corporation | $264.74 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Seagen INC. | $260.27 | 2019-2023 | Padcev, Tukysa |
| Novartis Pharmaceuticals Corporation | $251.30 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $213.44 | 2019-2025 | |
| Genentech USA, INC. | $207.41 | 2019-2023 | Venclexta |
| Lilly USA, LLC | $139.94 | 2019-2023 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjeev Gopal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.